Harel Insurance Investments & Financial Services Ltd. Sells 7,865 Shares of Gilead Sciences, Inc. (GILD)

Harel Insurance Investments & Financial Services Ltd. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 56.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,135 shares of the biopharmaceutical company’s stock after selling 7,865 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Gilead Sciences were worth $474,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in GILD. Reilly Financial Advisors LLC raised its position in Gilead Sciences by 98.3% in the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 704 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $132,000. Brand Asset Management Group Inc. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $139,000. TRUE Private Wealth Advisors acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $174,000. Finally, Wealthsource Partners LLC acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $206,000. 78.23% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ GILD opened at $70.90 on Tuesday. The company has a quick ratio of 3.39, a current ratio of 3.47 and a debt-to-equity ratio of 1.36. Gilead Sciences, Inc. has a 12 month low of $64.27 and a 12 month high of $89.54. The company has a market cap of $90.41 billion, a PE ratio of 8.28, a price-to-earnings-growth ratio of -3.52 and a beta of 1.01.



Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the previous year, the company posted $2.27 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 6.6 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.22%. Gilead Sciences’s dividend payout ratio is currently 26.64%.

In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total transaction of $3,708,000.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares in the company, valued at approximately $227,505,229.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 150,000 shares of company stock valued at $11,502,500 over the last quarter. 1.16% of the stock is currently owned by corporate insiders.

Several research firms have weighed in on GILD. Morgan Stanley boosted their price target on Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 26th. Piper Jaffray Companies set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Zacks Investment Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 25th. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Finally, Raymond James lowered their price target on Gilead Sciences from $97.00 to $94.00 and set a “strong-buy” rating on the stock in a research report on Friday. Thirteen investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $87.84.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: Fundamental Analysis and Individual Investors

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply